• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

确定结肠癌预后的最佳检查淋巴结数量:一项基于人群的研究,按肿瘤位置和T分期分层

Determining the optimal number of examined lymph nodes for prognosis in colon cancer: a population-based study stratified by tumor location and T stage.

作者信息

Zhou Jiahao, Yang Tinghan, Deng Xiangbing, Wang Ziqiang

机构信息

Colorectal Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.

出版信息

J Gastrointest Oncol. 2025 Feb 28;16(1):115-127. doi: 10.21037/jgo-24-576. Epub 2025 Jan 6.

DOI:10.21037/jgo-24-576
PMID:40115935
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11921217/
Abstract

BACKGROUND

Clinical guidelines recommend ≥12 examined lymph nodes (ELNs) for colon cancer staging, but more may be necessary for accuracy. This study utilized nodal staging scores (NSS) to identity the optimal number of ELNs based on tumor location and T stage, and to assess its prognostic impact.

METHODS

Data from 80,792 patients in the Surveillance, Epidemiology, and End Results (SEER) database (2004-2014) and 2,300 patients from the West China Hospital (WCH) cohort (2008-2014) with stage I-III resected colon cancer were analyzed. Optimal ELNs was estimated using a β-binomial distribution model, stratified by tumor location (left-sided, LS; right-sided, RS) and T stage. The primary outcome was overall survival (OS). The association between sufficient nodal staging and OS in node-negative patients was validated by multivariate Cox models.

RESULTS

The mean number of ELN was 18.75 in the SEER and 14.58 in the WCH database. There were 57.8% and 48.8% patients who had RS colon cancer in the SEER and WCH database. Fewer T3-4 tumors were observed in the SEER cohort compared to the WCH cohort (68.4% 87.2%). Sufficient nodal staging required ≥24 ELNs for T3 tumors, ≥34 nodes for T4 LS tumors, and ≥40 nodes for T4 RS tumors. For T3 lesions, examining 20-29 ELNs were more likely to have node-positive disease [odd ratio (OR) 1.07; 95% confidence interval (CI): 1.01-1.12] compared to patients with 12-15 ELNs. In the T3N0 group, ELN ≥24 was independently associated with better OS in the SEER database [hazard ratio (HR) 0.72; 95% CI: 0.68-0.75], which was validated in the WCH cohort (HR 0.54; 95% CI: 0.38-0.76).

CONCLUSIONS

Optimal ELNs for adequate colon cancer staging is related to both T stage and tumor location. We recommend that ≥24 lymph nodes be examined for T3 tumors, ≥34 for LS T4 tumors and ≥40 for RS T4 tumors for sufficient staging.

摘要

背景

临床指南推荐对结肠癌进行分期时需检查≥12枚淋巴结(ELN),但为保证准确性可能需要检查更多淋巴结。本研究利用淋巴结分期评分(NSS),根据肿瘤位置和T分期确定ELN的最佳数量,并评估其对预后的影响。

方法

分析了监测、流行病学和最终结果(SEER)数据库(2004 - 2014年)中80792例患者以及华西医院(WCH)队列(2008 - 2014年)中2300例I - III期结肠癌切除患者的数据。使用β - 二项分布模型估计最佳ELN数量,按肿瘤位置(左侧,LS;右侧,RS)和T分期分层。主要结局为总生存期(OS)。通过多变量Cox模型验证淋巴结阴性患者中充分的淋巴结分期与OS之间的关联。

结果

SEER数据库中ELN的平均数量为18.75,WCH数据库中为14.58。SEER和WCH数据库中分别有57.8%和48.8%的患者患有右半结肠癌。与WCH队列相比,SEER队列中观察到的T3 - 4期肿瘤较少(68.4%对87.2%)。T3期肿瘤充分的淋巴结分期需要≥24枚ELN,T4 LS期肿瘤需要≥34枚淋巴结,T4 RS期肿瘤需要≥40枚淋巴结。对于T3期病变,与检查12 - 15枚ELN的患者相比,检查20 - 29枚ELN的患者更有可能出现淋巴结阳性疾病[比值比(OR)1.07;95%置信区间(CI):1.01 - 1.12]。在T3N0组中,SEER数据库中ELN≥24与更好的OS独立相关[风险比(HR)0.72;95% CI:0.68 - 0.75],这在WCH队列中得到验证(HR 0.54;95% CI:0.38 - 0.76)。

结论

结肠癌充分分期的最佳ELN数量与T分期和肿瘤位置均相关。我们建议,为了充分分期,T3期肿瘤应检查≥24枚淋巴结,LS T4期肿瘤应检查≥34枚,RS T4期肿瘤应检查≥40枚。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af69/11921217/c33bf801cf73/jgo-16-01-115-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af69/11921217/5d13f3dda05d/jgo-16-01-115-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af69/11921217/258a5bb33be2/jgo-16-01-115-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af69/11921217/c33bf801cf73/jgo-16-01-115-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af69/11921217/5d13f3dda05d/jgo-16-01-115-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af69/11921217/258a5bb33be2/jgo-16-01-115-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af69/11921217/c33bf801cf73/jgo-16-01-115-f3.jpg

相似文献

1
Determining the optimal number of examined lymph nodes for prognosis in colon cancer: a population-based study stratified by tumor location and T stage.确定结肠癌预后的最佳检查淋巴结数量:一项基于人群的研究,按肿瘤位置和T分期分层
J Gastrointest Oncol. 2025 Feb 28;16(1):115-127. doi: 10.21037/jgo-24-576. Epub 2025 Jan 6.
2
Impact of examined lymph node count on staging and long-term survival of patients with node-negative stage III gastric cancer: a retrospective study using a Chinese multi-institutional registry with Surveillance, Epidemiology, and End Results (SEER) data validation.检查的淋巴结数量对Ⅲ期淋巴结阴性胃癌患者分期及长期生存的影响:一项使用中国多机构登记数据并经监测、流行病学和最终结果(SEER)数据验证的回顾性研究
Ann Transl Med. 2020 Sep;8(17):1075. doi: 10.21037/atm-20-1358a.
3
Determining the optimal number of examined lymph nodes for accurate staging of pancreatic cancer: An analysis using the nodal staging score model.确定用于准确分期胰腺癌的最佳检查淋巴结数量:使用淋巴结分期评分模型的分析。
Eur J Surg Oncol. 2019 Jun;45(6):1069-1076. doi: 10.1016/j.ejso.2019.01.018. Epub 2019 Jan 18.
4
A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.基于检查淋巴结数量相关特征的列线图模型预测胃癌的预后并指导临床治疗。
Front Immunol. 2022 Nov 2;13:947802. doi: 10.3389/fimmu.2022.947802. eCollection 2022.
5
The minimum number of examined lymph nodes was 24 for optimal survival of pathological T2-4 gastric cancer: a multi-center, hospital-based study covering 20 years of data.对于病理 T2-4 期胃癌患者,最佳生存的最低淋巴结检出数为 24 个:一项涵盖 20 年数据的多中心、以医院为基础的研究。
BMC Cancer. 2023 Sep 21;23(1):892. doi: 10.1186/s12885-023-11138-0.
6
Significance of Examined Lymph Node Number in Accurate Staging and Long-term Survival in Resected Stage I-II Pancreatic Cancer-More is Better? A Large International Population-based Cohort Study.在根治性切除的 I 期- II 期胰腺癌中,检查淋巴结数量对准确分期和长期生存的意义——更多更好?一项大型国际基于人群的队列研究。
Ann Surg. 2021 Dec 1;274(6):e554-e563. doi: 10.1097/SLA.0000000000003558.
7
The minimum number of examined lymph nodes for accurate nodal staging and optimal survival of stage T1-2 esophageal squamous cell carcinoma: A retrospective multicenter cohort with SEER database validation.为实现 T1-2 期食管鳞癌准确的淋巴结分期和最佳生存,所需检查的最少淋巴结数目:一项回顾性多中心队列研究及 SEER 数据库验证。
Int J Surg. 2022 Aug;104:106764. doi: 10.1016/j.ijsu.2022.106764. Epub 2022 Jul 6.
8
Prognostic and predictive value of examined lymph node count in stage III colorectal cancer: a population based study.III 期结直肠癌中检查淋巴结数的预后和预测价值:一项基于人群的研究。
World J Surg Oncol. 2024 Jun 13;22(1):155. doi: 10.1186/s12957-024-03404-7.
9
Determining the Adequate Examined Lymph Node Count in Resected Ampullary Adenocarcinoma-A National Cohort Study.确定切除的壶腹腺癌中适当的检查淋巴结数量-全国队列研究。
J Gastrointest Surg. 2018 May;22(5):792-801. doi: 10.1007/s11605-018-3737-6. Epub 2018 Mar 15.
10
Use of Nodal Staging Score in Evaluating the Accuracy of Pathologic Nodal Status in Node-Negative Ampullary Carcinoma.应用淋巴结分期评分评估阴性淋巴结的壶腹腺癌病理淋巴结状态的准确性。
J Gastrointest Surg. 2021 Apr;25(4):1001-1009. doi: 10.1007/s11605-020-04572-z. Epub 2020 Apr 6.

本文引用的文献

1
Lymph Node Yield and Long-Term Mortality Risk in Patients with Colon Cancer: A 20-Year Follow-Up National Study.结肠癌患者的淋巴结获取量与长期死亡风险:一项为期20年随访的全国性研究。
Ann Surg Oncol. 2025 Feb;32(2):1117-1127. doi: 10.1245/s10434-024-16428-w. Epub 2024 Nov 4.
2
Transverse colon cancer: a call for focused research in an understudied heterogenous disease.横结肠癌:呼吁对一种研究不足的异质性疾病开展针对性研究。
J Gastrointest Oncol. 2024 Aug 31;15(4):1981-1986. doi: 10.21037/jgo-24-312. Epub 2024 Aug 28.
3
Prognostic significance of negative lymph node count in microsatellite instability-high colorectal cancer.
微卫星不稳定高结直肠癌中阴性淋巴结计数的预后意义。
World J Surg Oncol. 2024 Jul 19;22(1):186. doi: 10.1186/s12957-024-03469-4.
4
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.《结肠癌临床实践指南(第 3.2024 版)》,NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2024 Jun;22(2 D). doi: 10.6004/jnccn.2024.0029.
5
Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.卡瑞利珠单抗联合阿帕替尼新辅助治疗局部晚期微卫星高度不稳定或错配修复缺陷型结直肠癌(NEOCAP):一项单臂、开放标签、Ⅱ期研究。
Lancet Oncol. 2024 Jul;25(7):843-852. doi: 10.1016/S1470-2045(24)00203-1. Epub 2024 Jun 6.
6
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
7
Construction of a diagnostic nomogram model for predicting the risk of lymph node metastasis in clinical T1 or T2 colon cancer based on the SEER database.基于监测、流行病学和最终结果(SEER)数据库构建诊断列线图模型,以预测临床T1或T2期结肠癌患者发生淋巴结转移的风险
Transl Cancer Res. 2024 Feb 29;13(2):1016-1025. doi: 10.21037/tcr-23-1451. Epub 2024 Jan 25.
8
Variation in Lymph Node Assessment for Colon Cancer at the Tumor, Surgeon, and Hospital Level.肿瘤、外科医生及医院层面结肠癌淋巴结评估的差异
J Am Coll Surg. 2024 Apr 1;238(4):520-528. doi: 10.1097/XCS.0000000000000963. Epub 2024 Mar 15.
9
Prognostic value of lymph node distribution after laparoscopic colectomy with Japanese D3 dissection.腹腔镜结直肠切除术日本 D3 解剖后淋巴结分布的预后价值。
Langenbecks Arch Surg. 2024 Jan 6;409(1):28. doi: 10.1007/s00423-023-03222-7.
10
Association of hemicolectomy with survival in stage II colorectal cancer: a retrospective cohort study.半结肠切除术与II期结直肠癌生存率的关联:一项回顾性队列研究。
Updates Surg. 2023 Dec;75(8):2211-2223. doi: 10.1007/s13304-023-01646-w. Epub 2023 Nov 24.